Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics
- PMID: 19888344
- PMCID: PMC2766032
- DOI: 10.1371/journal.pone.0007673
Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics
Abstract
Infection with Aspergillus terreus is more likely to result in invasive, disseminated disease when compared to other Aspergillus species; importantly this species appears to be less susceptible to the antifungal drug amphotericin B. Unique to this species is the ability to produce specialized structures denoted as accessory conidia (AC) directly on hyphae both in vitro and in vivo. With the hypothesis that production of AC by A. terreus may enhance virulence of this organism, we analyzed the phenotype, structure and metabolic potential of these conidia. Comparison of A. terreus phialidic conidia (conidia that arise from conidiophores, PC) and AC architecture by electron microscopy revealed distinct morphological differences between the two conidial forms; AC have a smoother, thicker outer cell surface with no apparent pigment-like layer. Further, AC germinated rapidly, had enhanced adherence to microspheres, and were metabolically more active compared to PC. Additionally, AC contained less cell membrane ergosterol, which correlated with decreased susceptibility to AMB as determined using a flow cytometry based analysis. Furthermore, AC exhibited surface patches of beta1-3 glucan, suggestive of attachment scarring. Collectively, the findings of this study suggest a possible role for AC in A. terreus pathogenesis.
Conflict of interest statement
Figures
Similar articles
-
Aspergillus terreus accessory conidia are multinucleated, hyperpolarizing structures that display differential dectin staining and can induce heightened inflammatory responses in a pulmonary model of aspergillosis.Virulence. 2011 May-Jun;2(3):200-7. doi: 10.4161/viru.2.3.15799. Epub 2011 May 1. Virulence. 2011. PMID: 21543882 Free PMC article.
-
Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.J Infect Dis. 2003 Jul 15;188(2):305-19. doi: 10.1086/377210. Epub 2003 Jul 9. J Infect Dis. 2003. PMID: 12854088
-
Characterization of Aspergillus terreus Accessory Conidia and Their Interactions With Murine Macrophages.Front Microbiol. 2022 Jun 16;13:896145. doi: 10.3389/fmicb.2022.896145. eCollection 2022. Front Microbiol. 2022. PMID: 35783442 Free PMC article.
-
Antifungal resistance in Aspergillus terreus: A current scenario.Fungal Genet Biol. 2019 Oct;131:103247. doi: 10.1016/j.fgb.2019.103247. Epub 2019 Jun 25. Fungal Genet Biol. 2019. PMID: 31247322 Review.
-
Aspergillus terreus: Novel lessons learned on amphotericin B resistance.Med Mycol. 2018 Apr 1;56(suppl_1):73-82. doi: 10.1093/mmy/myx119. Med Mycol. 2018. PMID: 29538736 Review.
Cited by
-
New insight into amphotericin B resistance in Aspergillus terreus.Antimicrob Agents Chemother. 2013 Apr;57(4):1583-8. doi: 10.1128/AAC.01283-12. Epub 2013 Jan 14. Antimicrob Agents Chemother. 2013. PMID: 23318794 Free PMC article.
-
Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility.Med Microbiol Immunol. 2013 Oct;202(5):379-89. doi: 10.1007/s00430-013-0300-7. Epub 2013 May 31. Med Microbiol Immunol. 2013. PMID: 23722593
-
Hide, Keep Quiet, and Keep Low: Properties That Make Aspergillus fumigatus a Successful Lung Pathogen.Front Microbiol. 2016 Apr 6;7:438. doi: 10.3389/fmicb.2016.00438. eCollection 2016. Front Microbiol. 2016. PMID: 27092115 Free PMC article.
-
A retrospective multi-center study of treatment, outcome, and prognostic factors in 34 dogs with disseminated aspergillosis in Australia.J Vet Intern Med. 2022 Mar;36(2):580-590. doi: 10.1111/jvim.16366. Epub 2022 Jan 27. J Vet Intern Med. 2022. PMID: 35085412 Free PMC article.
-
Invasive Aspergillus terreus morphological transitions and immunoadaptations mediating antifungal resistance.Infect Drug Resist. 2017 Nov 7;10:425-436. doi: 10.2147/IDR.S147331. eCollection 2017. Infect Drug Resist. 2017. PMID: 29158685 Free PMC article.
References
-
- Magill SS, Chiller TM, Warnock DW. Evolving strategies in the management of aspergillosis. Expert Opin Pharmacother. 2008;9:193–209. - PubMed
-
- Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs. 2007;67:1803–1812. - PubMed
-
- Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, Perfect JR, Lutsar I, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192–198. - PubMed
-
- Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188:305–319. - PubMed
-
- Raper BK, Fennell DI. Baltimore, Md: The Williams and Wilkins Company; 1965. The Genus Aspergillus.657
MeSH terms
Substances
LinkOut - more resources
Full Text Sources